AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06734195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: patients will receive caudal dexmedetomidine block using 1 ml/kg of bupivacaine 0. 25 % mixed with dexmedetomidie 1mic/kg diluted in 2 ml normal saline
Study NCT06145516 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for insomnia (CBT-I)
Description: Hybrid CBT-I (self-guided digital format focusing on sleep restriction therapy and stimulus control + telehealth video-consultations with psychologist)
Study NCT06145516 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep education therapy (SET)
Description: Self-guided digital sleep education (sleep hygiene, sleep physiology, sleep disturbances etc) + telehealth video-consultations with research nurse
Study NCT04640974 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cingal
Description: Single injection into the ankle joint of a 4 ml unit dose of Cingal containing 88 mg (22 mg/ml) of cross-linked sodium hyaluronate and 18 mg (4.5 mg/ml) of triamcinolone hexacetonide (TH).
Study NCT05639413 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Collection of blood samples
Description: A 30 mL blood samples (6 mL in each of 5 EDTA tubes) will be collected from each patient at each timepoint.
Study NCT05894265 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ActiveMatrix® Dosage A
Description: This group will receive ActiveMatrix® (AM) product dosage A (1cc AM diluted to 3cc with saline)
Study NCT05894265 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ActiveMatrix® Dosage B
Description: Group 2 will receive ActiveMatrix® product dosage B (2cc AM diluted to 3cc with saline)
Study NCT05894265 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Saline injection
Description: Group 3 will receive saline injection
Study NCT06476314 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Glasses Group
Description: Apart from the routine clinic procedure, VR video scenes (contain nature views) will be watched for 5-10 minutes during the procedure.
Study NCT06476314 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stress Ball Group
Description: Apart from the routine clinic procedure, it will be asked squeezing the stress ball for about 5-10 minutes (squeezing it once every time he counts to five)during the procedure.
Study NCT05546450 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: Patient in Diet Group and Cornus mas L. and Diet Group will be given a personalized diet and be followed up by a dietician.
Study NCT05546450 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cornus mas L.(Cornelian Cherry)
Description: Patients in Cornus mas L. Group and Cornus mas L. and Diet Group will receive 30 g/day freeze-dried Cornus mas L. fruit powder supplement.
Study NCT06224309 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 18F-BL40 PET/CT
Description: Vital signs will be recorded prior to the BL40 injection. Each study subject will have an intravenous catheter inserted. Prior to the radiotracer injection an ultra low dose CT will be taken. Subjects are positioned supine, arms down. The subject will receive a bolus intravenous dose of the 18F-BL40 from an approved study supplier site. A Dynamic PET scan will be taken of the heart. Then a serial whole body PET scan will be done. Vital signs will be taken again and the subject will have a bathroom break. The patient will return to the scanner bed for a standard low dose CT and whole body PET scan. Vital signs will be taken again, and subject will be allowed to use the washroom again. The subject will return to the scanner bed for the final time for an ultra low dose CT and whole body PET scan. A final set of vitals will be taken and the subject will be discharged.
Study NCT06224309 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 18F-FDG PET/CT
Description: The patient will return on another day for the 18F-FDG PET/CT scan. A fasting period of 6 hours is required before this scan.~Each study subject will have an intravenous catheter inserted. The subject will receive a bolus intravenous dose of the radiotracer from an approved study supplier site.~The subject will rest in a comfortable chair for 60 minutes. The subjects will then be taken to a designated washroom and asked to void prior to being scanned in order to clear excreted radiotracer activity from the urinary tract.~Subjects are positioned supine, arms down, and centered on the scanner bed and the PET/CT images will be acquired.
Study NCT06224309 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Routine Blood Draw - Phase 1 only
Description: Complete blood counts and routine clinical chemistry performed before and repeated within 18-72 hours after 18F-BL40 administration.
Study NCT05149183 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cervical stability training
Description: cervical stability training will be contain three phases, each phase has six positions ( supine, forearms, sidelying, four point kneeling, sitting and standing position)
Study NCT05149183 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional treatment
Description: TENS, hot packs, stretching exercise of superficial neck muscles, and postural advice.
Study NCT05149183 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional treatment
Description: TENS, hot packs, stretching exercise of superficial neck muscles, and postural advice.
Study NCT05867082 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neural Mobilization
Description: Radial Nerve Mobilization, Medial Mobilization, Ulnar Mobilization
Study NCT06426485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toludesvenlafaxine Hydrochloride Sustained-release Tablets
Description: orally once a day
Study NCT06426485 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: orally once a day
Study NCT05934162 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapist-supported internet-delivered prolonged exposure
Description: 10 weeks of therapist-supported internet-delivered prolonged exposure
Study NCT05934162 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapist-supported internet-delivered CBT
Description: 10 weeks of therapist-supported internet-delivered CBT
Study NCT04764851 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ecopipam HCl ~2mg/kg/day
Description: oral tablet
Study NCT04764851 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Cohort 1 Probe Cocktail
Description: dextromethorphan, caffeine, omeprazole, and midazolam
Study NCT04764851 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Cohort 2 Probe Cocktail
Description: dabigatran, pitavastatin, rosuvastatin, atorvastatin, midazolam
Study NCT04764851 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Cohort 3 Probe Cocktail
Description: bupropion
Study NCT04900558 — intervention group
Intervention type: PROCEDURE
Intervention: Radical Cystectomy
Description: All the patients enrolled have undergone or will undergo radical cystectomy, with or without lymphadenectomy or urethrectomy All possibles urinary diversion are included, like ileal conduit, neobladder etc...
Study NCT06470399 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy group
Description: Participants receive DS prescriptions from a physician based on current standard practices, which include biochemical markers, genetic data, and metabolic profiles.
Study NCT06470399 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AI-Guided Group
Description: Participants receive DS prescriptions determined by GenAIS, is an AI system that considers genetic data, metabolic profiles, biochemical markers, and patient history.
Study NCT05024305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TWP-102 injection
Description: IV infusion
Study NCT05340725 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DEX-IV
Description: patients will receive iv DEX 1µ/kg diluted in 100 ml saline and given slowly iv infusion over 10 min. 30 min. before induction of anesthesia.
Study NCT05340725 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DEX-Rectal
Description: Patients will receive rectal DEX suppository formulation at approximately 1µ/kg at 30 min. before induction of anesthesia
Study NCT05340725 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DEX-Nano-Rectal
Description: Patients will receive rectal DEX suppository in the Niosomes formulation at approximately 1µ/kg at 30 min. before induction of anesthesia
Study NCT05491252 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PAtient CEntered Self-Management Intervention (PACE-SMI)
Description: Week 1: General disease knowledge. Week 2: Role of self-care behaviors towards effective management of type 2 diabetes, motivational video and real story of a diabetic patient to serve as a role-model. Lastly, provision of diabetes self-care guidebook.~Week 3: Home visit to observe facilitators and barriers on initiating and maintaining behavioral change with social support as a key strategy.~Week 4: ECB session on Diet. Week 5: ECB session on Physical Activity. Week 6: ECB session on Foot Care. Week 7: ECB session on Medication Adherence. Week 8: Booster session comprising reflection, performance feedback and review of behavioral goals fostering continued performance accomplishment and addressing difficulties of maintaining behaviour change over time.
Study NCT05665491 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HabitWorks
Description: Smartphone app-delivered interpretation bias intervention
Study NCT05665491 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Assessment
Description: Self-assessment of parenting behaviors and anxiety symptoms
Study NCT05665491 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Self-Assessment
Description: Self-assessment of parenting behaviors and anxiety symptoms
Study NCT01471314 — intervention group
Intervention type: BEHAVIORAL
Intervention: Headache day versus non-headache day
Study NCT06490302 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens A (ocufilcon D)
Description: 15 minutes of daily wear
Study NCT06490302 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens B (fanfilcon A)
Description: 15 minutes of daily wear
Study NCT05171946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S.opt.FL COVID-19 pDNA vaccine
Description: Low-Dose: (1mg) level
Study NCT05171946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S.opt.FL COVID-19 pDNA vaccine
Description: Mid-Dose: (2mg) level
Study NCT05171946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S.opt.FL COVID-19 pDNA vaccine
Description: High-Dose: (4mg) level
Study NCT04137640 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: palbociclib combined with letrozole
Description: Endocrine group will receive palbociclib combined with letrozole: palbociclib (Pfizer Manufacturing Deutschland GmbH, Freiburg, Germany; license number: H20180040) 125 mg/d, every 28 days as a cycle (medication for 3 consecutive weeks and withdrawal for 1 week); letrozole (Novartis Pharma Schweiz AG, Stein, Switzerland; license number: H20140149) 2.5 mg/d, for 6 consecutive months.
Study NCT04137640 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: epirubicin combined with cyclophosphamide and sequential docetaxel
Description: Chemotherapy group will receive epirubicin combined with cyclophosphamide and sequential docetaxel: epirubicin (Pfizer Wuxi Pharmaceutical Plant, Wuxi, China; license number: GYZZ H20000496), 90 mg/m2, intravenously, for 120 minutes, once every four weeks, totally four times; cyclophosphamide (Baxter Oncology GmbH, Halle, Germany; license number: H20160468), 600 mg/m2, once every four weeks, totally four times; sequential docetaxel (Sanofi-aventis Deutschland GmbH, Frankfurt am Main, Germany; license number: GYZZ J20150083) 75 mg/m2, intravenously, for 120 minutes, once every four weeks, totally four times.
Study NCT05023863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alpha Lipoic Acid 600 MG Oral Tablets
Description: Alpha Lipoic Acid (ALA) is a drug which has been used in treatment of diabetic neuropathy . It act through enhancing nitric oxide-mediated endothelium-dependent vasodilation, thus improving microcirculation in patients with diabetic polyneuropathy. It is considered a safe drug, generally with a daily dose of 200 to 2400 mg/day is considered tolerable without significant side effects. Only gastrointestinal tracts side effects like nausea, vomiting, dyspepsia and abdominal pain have been described in some clinical trials. Also FDA experts confirm its safety and efficacy in humans
Study NCT05023863 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets
Description: placebo tablets of the same generic of active drug which contain all the same ingredients as active tablets except alpha lipoic acid
Study NCT05023863 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation or concurrent chemoradiation
Description: radiation or concurrent radiotherapy plus platinum-based chemotherapy
Study NCT05023863 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: radiation or concurrent chemoradiation
Description: radiation or concurrent radiotherapy plus platinum-based chemotherapy
Study NCT05149027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HBM4003 and Triprilimab
Description: Subjects will be treated with HBM4003 and Toripalimap on Day 1 during each 21-day cycles.
Study NCT06191484 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WELL Behavioral Probe
Description: Participant record the timing and regularity of sleep, meals, and social activity twice daily, for 3 months, using a digital diary. Participants also receive weekly motivational health coaching.
Study NCT06231576 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: * Nutritional optimization: A nutritionist will perform a structured interview, comprehensive nutrition assessment, and provide personalized dietary advice. The main goal is to ensure optimal protein intake to support exercise-induced anabolism. A daily protein intake of 1.2-2.0 g/kg will meet needs as outlined in surgical nutrition guidelines.~* Exercise: Based on current guidelines and instructed by a dedicated physiotherapist, for 1 hour per day preoperatively to increase muscle strength, aerobic capacity and physical endurance. Intensity will be based on the rate of perceived exertion using the Borg scale, a 15-graded scale ranging from very light to very hard. Resistance exercises will target upper/lower body, and abdominal muscles.~* Psychological coaching and support: Performed as one interview during inclusion, followed by weekly phone calls by a study nurse coordinator during the preoperative intervention.
Study NCT05893784 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of progressive relaxation exercises education
Description: Progressive relaxation exercises education It starts with deep breathing exercises along with music. Then stretching and relaxation exercises are performed. After the education, an 8-minute video in which the progressive relaxation exercises was explained practically to the individuals was sent to their mobile phones. The participants were asked to perform these exercises regularly for 4 weeks, each day one hour before going to bed, simultaneously with the video.
Study NCT05445271 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Optic nerve sheath diameter measurement with linear ultrasound
Description: In this study, we aimed to show whether endotracheal intubation or LMA applications with optic nerve sheath diameter measurement, which is a completely non-invasive method, have effects on intracranial pressure.
Study NCT06459206 — intervention group
Intervention type: DEVICE
Intervention: Pulse oximeter
Description: Devices (4) were placed on the finger base and the fingertip of two right or left fingers and placed in motion for the duration of the study. Devices (3) were placed on the contralateral side and maintained motionless for the duration of the of study. Blood samples were taken at each stable level of oxygenation.
Study NCT05111041 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: #EnufSnuff.TXT- First Responder
Description: Participants in this intervention will be given the choice of following the Gradual Reduction to Quit program or to choose their own quit date within 2-4 weeks. The Gradual Reduction to Quit program will reduce smokeless tobacco use via text message support and weekly prompts guiding the participants to gradually decrease their use of smokeless tobacco until they are down to zero. A four week Nicotine Replacement Therapy (NRT) sample in the form of lozenges will also be provided to all participants. The intent of this program is to reduce the number of times participants use smokeless tobacco.
Study NCT05111041 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enough Snuff Intervention
Description: Participants will be sent the Enuf Snuff cessation manual, support text messages, as well as a four week Nicotine Replacement Therapy (NRT) sample in the form of lozenges.
Study NCT05050942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAM2029
Description: CAM2029 (octreotide subcutaneous depot) 20 mg will be administered every 2 weeks as a subcutaneous injection
Study NCT05050942 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide LAR
Description: Octreotide LAR 30 mg will be administered every 4 weeks as an intramuscular injection
Study NCT05050942 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lanreotide ATG
Description: Lanreotide ATG 120 mg will be administered every 4 weeks as a deep subcutaneous injection
Study NCT06476574 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vacuum-formed retainer
Description: * After patient finishes orthodontic treatment, the fixed orthodontic appliance will be debonded; finishing and polishing of the enamel surface will be done.~* An alginate impression will be taken to be poured into a working model for fabrication of the Vacuum-formed retainer; 1mm Hard vacuum sheet will be used.~* The retainer will be finished and delivered to the patient.~* The patient will be instructed to wear the retainer night time only and to contact us if any damage occurred to the retainers for immediate replacement; and he will be supplied with a check list to evaluate the compliance and to calculate the wearing hours.~* Another alginate impression will be taken for fabrication of the study model which will later be scanned to obtain the digital model at T0; and a periodontal chart will be filled to record the periodontal status at T0 (before wearing of the retainer).
Study NCT06476574 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combined Vacuum-formed and Lingual bonded retainer from canine-to-canine.
Description: * A multistrand rectangular stainless steel retainer wire will be bonded to the lingual surface of the lower anterior teeth, from the canine-to-canine bonded to all six anteriors; followed by an alginate impression; the impression will be poured into a working model for fabrication of the Vacuum-formed retainer; 1mm Hard vacuum sheet will be used \& it will be finished and delivered to the patient.~* The patient will be instructed to wear the Vacuum retainer night time only and to contact us if any damage occurred to the retainers for immediate replacement or rebonding of the detached parts of the bonded retainer; and will be supplied with a check list to evaluate the compliance and to calculate the wearing hours.~* Another alginate impression will be taken (with the bonded retainer in place) for fabrication of the study model which will later be scanned to obtain the digital model at T0; and a periodontal chart will be filled to record the periodontal status at T0.
Study NCT06476574 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lingual bonded retainer from canine-to-canine
Description: * After patient finishes orthodontic treatment, the fixed orthodontic appliance will be debonded; finishing and polishing of the enamel surface will be done.~* A multistrand rectangular stainless steel retainer wire will be bonded to the lingual surface of the lower anterior teeth, from the canine-to-canine bonded to all six anteriors.~* The patient will be instructed to contact us if any damage occurred to the retainers for immediate replacement or rebonding of the detached parts of the retainer.~* An alginate impression will be taken (with the bonded retainer in place) for fabrication of the study model which will later be scanned to obtain the digital model at T0; and a periodontal chart will be filled to record the periodontal status at T0 (at the same visit of the delivery of the bonded retainer).
Study NCT06325618 — intervention group
Intervention type: OTHER
Intervention: No intervention other than obtaining biopsies
Description: Skin, fat, and muscle biopsies will be obtained
Study NCT06325618 — intervention group
Intervention type: DRUG
Intervention: Indocyanine green (ICG)
Description: Indocyanine green will be injected to evaluate the lymphatic system.
Study NCT06418217 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise and Patient Education
Description: Patients will undergo a 12-week physiotherapist-led exercise program consisting of 8 supervised sessions and home-based training in between.~Patients will keep training diaries, where each session is tracked in regards of completed repetitions and pain before and after the sessions. Each session will consist of four exercises.
Study NCT04769050 — intervention group
Intervention type: DRUG
Intervention: Docetaxel combined with Trastuzumab±Pertuzumab
Description: Docetaxel, 75 mg/m2 ivgtt d1 q3w Trastuzumab, 6 mg/kg(8 mg/kg for initial dose) ivgtt d1 q3w Pertuzumab, 420mg(840mg for initial dose) ivgtt d1 q3w
Study NCT04769050 — intervention group
Intervention type: DRUG
Intervention: T-DM1 or Capecitabine combined with Pyrotinib regimen.
Description: T-DM1, 3.6mg/kg(8 mg/kg for initial dose) ivgtt d1 q3w Capecitabine, 1250 mg/m2 bid po d1-14 q3w Pyrotinib, 400mg po daily (continuously)